The Expert Committee recommended addition of nevirapine 50 mg dispersible tablet formulation to the core list of the EML and EMLc for the treatment of children and adolescents with HIV-1 infection. The Expert Committee agreed on the public health need for paediatric formulations of ART medicines and considered that the proposed formulation of nevirapine represented a rational treatment option for paediatric HIV patients. The Committee noted that this formulation is included in the 2013 WHO guidelines and are categorized by the IATT as an“optimal” paediatric formulation.